Jennifer Riley Takes on Chief Strategy Role at Avalo Therapeutics

Avalo Therapeutics Welcomes Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics, Inc. (NASDAQ: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, has appointed Jennifer Riley as their new Chief Strategy Officer. This position is effective immediately. Ms. Riley's expertise is expected to elevate Avalo's corporate strategy, focusing on commercial and product pipeline advancements.

Jennifer Riley's Background

Dr. Garry Neil, the CEO and Chairman of Avalo, expressed excitement about Jennifer joining the team in this pivotal role. He noted her extensive leadership in immunology and strategic planning as key advantages for Avalo as they pursue their innovative treatments, particularly AVTX-009, which is currently in the LOTUS Phase 2 trial targeting hidradenitis suppurativa.

The Impact of AVTX-009

Ms. Riley highlighted the significant potential for AVTX-009 to emerge as a leading treatment for hidradenitis suppurativa (HS), a condition that presents high unmet medical need and is part of a fast-growing market predicted to exceed $10 billion. Her commitment to exploring the further applications of AVTX-009 demonstrates the ambition Avalo holds for its product pipeline, underlining IL-1?'s relevance in various inflammatory diseases.

Ms. Riley's Professional Journey

With over 20 years in the biotechnology and pharmaceutical sectors, Ms. Riley has been instrumental in shaping development strategies and optimizing portfolios for numerous firms. Prior to this, she led initiatives at Biogen, including overseeing the company's hemophilia portfolio. Her extensive background highlights her ability to deliver results in therapeutic areas spanning immunology and rare diseases.

Defined Role and Responsibilities

As Chief Strategy Officer, her responsibilities encompass refining Avalo's strategies for commercialization and innovation. This strategic role involves significant oversight of product development, aiming to ensure that Avalo not only meets but also anticipates market demands.

About Inducement Grants

Avalo's Board of Directors granted Ms. Riley a non-qualified stock option allowing her to purchase 150,000 shares of common stock. The structure of this option ensures that it vests over four years, reflecting Avalo's commitment to rewarding their leadership.

Unprecedented Market Opportunities

As Avalo Therapeutics continues to advance its lead asset, it is also pursuing two other drug candidates: quisovalimab (an anti-LIGHT mAb) and AVTX-008 (a BTLA agonist fusion protein). These additions reinforce Avalo's commitment to expanding its impact within the treatment of immune dysregulation.

LOTUS Trial Overview

The LOTUS Trial focuses on evaluating AVTX-009’s efficacy and safety through a structured, randomized approach across various dosing regimens. The trial aims to engage approximately 180 adults suffering from moderate to severe HS, establishing benchmarks based on key clinical responses.

Addressing Hidradenitis Suppurativa

Hidradenitis suppurativa is a distressing chronic inflammatory skin disorder characterized by painful nodules and abscesses, often located in areas such as the armpits and groin. This condition is frequently underdiagnosed, affecting up to 1.7% of the global population.

Contact Information for Inquiries

For media or investor-related inquiries, please reach out to Christopher Sullivan, CFO of Avalo Therapeutics, at ir@avalotx.com or call 410-803-6793. Additional inquiries can be directed to Lauren Glaser at Meru Advisors at lglaser@meruadvisors.com.

Frequently Asked Questions

Who is Jennifer Riley?

Jennifer Riley has been appointed as the Chief Strategy Officer at Avalo Therapeutics, bringing extensive leadership experience in biotechnology.

What is AVTX-009?

AVTX-009 is an anti-IL-1? monoclonal antibody currently in development for treating hidradenitis suppurativa and other inflammatory diseases.

What does the LOTUS Trial entail?

The LOTUS Trial assesses the efficacy and safety of AVTX-009 in adults with moderate to severe hidradenitis suppurativa.

How will Ms. Riley's role impact Avalo Therapeutics?

Ms. Riley's role will enhance Avalo's corporate strategy, focusing on innovation and commercialization of its drug candidates.

What is hidradenitis suppurativa?

Hidradenitis suppurativa is a chronic skin condition marked by painful abscesses that can significantly impact quality of life.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.